Plasma Cytokine Atlas Reveals the Importance of TH2 Polarization and Interferons in Predicting COVID-19 Severity and Survival.

COVID-19 SARS-CoV-2 chemokines cytokines survival

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 23 12 2021
accepted: 21 02 2022
entrez: 7 4 2022
pubmed: 8 4 2022
medline: 9 4 2022
Statut: epublish

Résumé

Although it is now widely accepted that host inflammatory response contributes to COVID-19 immunopathogenesis, the pathways and mechanisms driving disease severity and clinical outcome remain poorly understood. In the effort to identify key soluble mediators that characterize life-threatening COVID-19, we quantified 62 cytokines, chemokines and other factors involved in inflammation and immunity in plasma samples, collected at hospital admission, from 80 hospitalized patients with severe COVID-19 disease who were stratified on the basis of clinical outcome (mechanical ventilation or death by day 28). Our data confirm that age, as well as neutrophilia, lymphocytopenia, procalcitonin, D-dimer and lactate dehydrogenase are strongly associated with the risk of fatal COVID-19. In addition, we found that cytokines related to TH2 regulations (IL-4, IL-13, IL-33), cell metabolism (lep, lep-R) and interferons (IFNα, IFNβ, IFNγ) were also predictive of life-threatening COVID-19.

Identifiants

pubmed: 35386702
doi: 10.3389/fimmu.2022.842150
pmc: PMC8979161
doi:

Substances chimiques

Chemokines 0
Cytokines 0
Interferons 9008-11-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

842150

Informations de copyright

Copyright © 2022 Gibellini, De Biasi, Meschiari, Gozzi, Paolini, Borella, Mattioli, Lo Tartaro, Fidanza, Neroni, Busani, Girardis, Guaraldi, Mussini, Cozzi-Lepri and Cossarizza.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Eur J Immunol. 2021 Dec;51(12):2708-3145
pubmed: 34910301
Nat Commun. 2021 Jul 5;12(1):4117
pubmed: 34226537
Sci Rep. 2020 Oct 29;10(1):18689
pubmed: 33122784
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4
pubmed: 32360286
Eur J Immunol. 2022 Mar;52(3):484-502
pubmed: 34870329
EMBO Mol Med. 2020 Dec 7;12(12):e13001
pubmed: 33078545
JCI Insight. 2021 Aug 9;6(15):
pubmed: 34185704
Sci Immunol. 2021 Mar 10;6(57):
pubmed: 33692097
Nat Rev Immunol. 2021 Jan;21(1):49-64
pubmed: 33214719
Front Immunol. 2021 Apr 26;12:668507
pubmed: 33981314
Respir Med Case Rep. 2020;31:101292
pubmed: 33200067
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Cytometry A. 2020 Apr;97(4):340-343
pubmed: 32187834
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
PLoS One. 2013;8(2):e57121
pubmed: 23468921
Int J Obes Relat Metab Disord. 2003 Dec;27(12):1472-8
pubmed: 14634677
Endocr Rev. 2007 Aug;28(5):492-520
pubmed: 17475924
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
Cytometry A. 2020 Jul;97(7):668-673
pubmed: 32275124
Front Cell Infect Microbiol. 2021 Feb 26;11:624483
pubmed: 33718270
Lancet Respir Med. 2021 Jun;9(6):622-642
pubmed: 33965003
Nat Rev Immunol. 2004 May;4(5):371-9
pubmed: 15122202
Nature. 2021 Mar;591(7848):92-98
pubmed: 33307546
Nat Commun. 2021 Jul 29;12(1):4677
pubmed: 34326336
Front Immunol. 2021 Jun 18;12:649359
pubmed: 34220807
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Sci Rep. 2021 Apr 13;11(1):8059
pubmed: 33850184
Cells. 2021 Jun 23;10(7):
pubmed: 34201847
Am J Respir Crit Care Med. 2013 Jan 1;187(1):65-77
pubmed: 23144331
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Eur J Immunol. 2020 Sep;50(9):1283-1294
pubmed: 32910469
Front Immunol. 2019 Dec 13;10:2759
pubmed: 31921102
Virus Res. 2020 Nov;289:198171
pubmed: 32979474
Cytokine Growth Factor Rev. 2020 Jun;53:25-32
pubmed: 32446778
Cell. 2020 Oct 29;183(3):837
pubmed: 33125895
Rev Med Virol. 2021 Jul;31(4):e2199
pubmed: 34260778

Auteurs

Lara Gibellini (L)

Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy.

Sara De Biasi (S)

Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy.

Marianna Meschiari (M)

Infectious Diseases Clinics, Azienda Ospedaliera-Universitaria (AOU) Policlinico and University of Modena and Reggio Emilia, Modena, Italy.

Licia Gozzi (L)

Infectious Diseases Clinics, Azienda Ospedaliera-Universitaria (AOU) Policlinico and University of Modena and Reggio Emilia, Modena, Italy.

Annamaria Paolini (A)

Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy.

Rebecca Borella (R)

Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy.

Marco Mattioli (M)

Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy.

Domenico Lo Tartaro (D)

Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy.

Lucia Fidanza (L)

Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy.

Anita Neroni (A)

Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy.

Stefano Busani (S)

Department of Anesthesia and Intensive Care, Azienda Ospedaliera-Universitaria (AOU) Policlinico and University of Modena and Reggio Emilia, Modena, Italy.

Massimo Girardis (M)

Department of Anesthesia and Intensive Care, Azienda Ospedaliera-Universitaria (AOU) Policlinico and University of Modena and Reggio Emilia, Modena, Italy.

Giovanni Guaraldi (G)

Infectious Diseases Clinics, Azienda Ospedaliera-Universitaria (AOU) Policlinico and University of Modena and Reggio Emilia, Modena, Italy.

Cristina Mussini (C)

Infectious Diseases Clinics, Azienda Ospedaliera-Universitaria (AOU) Policlinico and University of Modena and Reggio Emilia, Modena, Italy.

Alessandro Cozzi-Lepri (A)

Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, London, United Kingdom.

Andrea Cossarizza (A)

Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy.
National Institute for Cardiovascular Research, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH